Roche has reported first-half 2026 group revenue of CHF 30.4 billion (USD 38.4 billion), up 6% in constant exchange rates, with pharmaceutical sales of CHF 23.7 billion (USD 29.9 billion, +6%) and diagnostics sales of CHF 6.7 billion (USD 8.5 billion, +3%). Five assets surpassed USD 2 billion in sales – Ocrevus, Hemlibra, Vabysmo, Tecentriq, and Xolair. R&D expenditure reached CHF 5.8 billion (USD 7.3 billion), representing 19.0% of total turnover, sustaining Roche's high-investment innovation model.

The group is advancing its metabolic franchise through enicepatide, a GLP-1R/GIPR co-agonist in obese patients with type 2 diabetes (T2D), and petrelintide, an amylin analogue showing promising weight-loss potential. These programmes complement Roche's recent in-licensing of Mabwell's B7-H3 ADC YL201 and position the company to contest the incretin and next-wave obesity market alongside Novo Nordisk and Eli Lilly.

Roche guided mid-single-digit group sales growth for full-year 2026, balancing mature oncology cash flows against pipeline transition risk.